Pulmagen Therapeutics (Asthma) Ltd.

Argenta, the New Zealand-founded global animal health pharmaceutical services company, has closed on the carve-out acquisition of the manufacturing site and operations in Shawnee, Kansas, USA from TriRx Pharmaceuticals. The acquisition strengthens Argenta’s ‘molecule to market’ strategy and integrated value proposition for customers. As part of the Argenta platform, the Shawnee facility will continue to operate as a provider of end-to-end CDMO services to the animal health industry. With a well-rounded set of capabilities, the site is ideally-positioned to continue growing with existing strategic customers as well as new potential clients looking for a partner to help develop and manufacture their in-market portfolios and future pipeline products. “We have long admired the team and operations at the Shawnee site and believe this is a transformational addition to our platform at Argenta,” said Johnny Kim, director at KKR and board member at Argenta. KKR acquired Argenta from the Tomlinson Group in 2020. “With our ability to now offer a truly end-to-end service for customers across the value chain combined with our dedicated and intentional focus towards serving the animal health industry – we believe we have a unique opportunity to become the clear, go-to strategic partner for customers in our ecosystem,” Kim continued.